Larinate® 60mg for injection

Ipca

Product category
  • Severe malaria treatment (artesunate for injection)

Therapeutic indication
  • Treatment of severe malaria caused by the parasite P. falciparum, to be followed by a full course of ACT

Dosing
  • At least three injections within 1 day during critical phase

Efficacy
  • 92% survival vs 88% survival with quinine in African children

  • Coma duration, convulsions, and hypoglycaemia significantly lower with artesunate compared to quinine

Key features
  • Increased global supply of artesunate for injection

  • Cost per disability-adjusted life year (DALY) averted: US$ 3.8

  • 3-year shelf life
Challenges
  • Potential for delayed haemolytic anaemia

  • Continued use of quinine or artemether for injection

  • Must be followed up with ACT to avoid artemisinin monotherapy use
Status
  • WHO prequalification in 2018
  • Approved in 21 countries; 17.4 million Larinate┬« vials shipped since prequalification*
Next milestone
  • Simplified injectable artesunate two-vial to be developed for WHO prequalification review

  • Additional country registrations

MMV Project Director
  • Hans Rietveld

* up to and including 2021